Bullish
$EXEL EXEL & BMY Collaborations. Clinical Trials. Phase 2 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (CheckMate040)